Corcept Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, CORT, Corcept Therapeutics Inc, priceseries

Corcept Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
23.57
Close
24.08
High
24.40
Low
23.34
Previous Close
23.67
Daily Price Gain
0.41
YTD High
24.40
YTD High Date
Mar 7, 2022
YTD Low
16.47
YTD Low Date
Jan 27, 2022
YTD Price Change
3.74
YTD Gain
18.39%
52 Week High
26.33
52 Week High Date
Mar 16, 2021
52 Week Low
15.83
52 Week Low Date
Dec 8, 2021
52 Week Price Change
0.33
52 Week Gain
1.39%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 22. 2017
8.51
Mar 14. 2017
9.69
14 Trading Days
13.83%
Link
LONG
Mar 24. 2017
10.12
Apr 5. 2017
10.79
8 Trading Days
6.63%
Link
LONG
May 11. 2017
10.04
May 30. 2017
11.57
12 Trading Days
15.27%
Link
LONG
Aug 28. 2017
14.69
Sep 21. 2017
17.41
17 Trading Days
18.51%
Link
LONG
Sep 22. 2017
18.20
Oct 10. 2017
19.32
12 Trading Days
6.13%
Link
LONG
Jan 9. 2018
19.94
Jan 30. 2018
23.26
14 Trading Days
16.64%
Link
LONG
Mar 7. 2018
15.77
Mar 20. 2018
17.49
9 Trading Days
10.91%
Link
LONG
May 14. 2018
17.16
May 31. 2018
18.51
12 Trading Days
7.89%
Link
LONG
Dec 11. 2018
17.17
Dec 12. 2018
18.33
1 Trading Days
6.73%
Link
LONG
Jan 10. 2019
13.89
Jan 22. 2019
14.71
7 Trading Days
5.87%
Link
LONG
Nov 7. 2019
14.60
Nov 20. 2019
15.60
9 Trading Days
6.85%
Link
LONG
Jan 10. 2020
12.33
Jan 30. 2020
13.04
13 Trading Days
5.75%
Link
LONG
May 14. 2020
13.70
Jun 2. 2020
14.63
12 Trading Days
6.76%
Link
LONG
Jun 15. 2020
15.23
Jul 6. 2020
16.78
14 Trading Days
10.20%
Link
LONG
Nov 18. 2020
18.66
Dec 29. 2020
26.06
27 Trading Days
39.66%
Link
LONG
Nov 4. 2021
20.09
Nov 23. 2021
22.65
13 Trading Days
12.74%
Link
Company Information
Stock Symbol
CORT
Exchange
NasdaqCM
Company URL
http://www.corcept.com
Company Phone
650.688.8803
CEO
Joseph K. Belanoff
Headquarters
California
Business Address
149 COMMONWEALTH DRIVE, MENLO PARK, CA 94025
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001088856
About

Corcept Therapeutics, Inc. engages in the development of drugs for the treatment of severe psychiatric, neurological, and metabolic disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff On May 13, 1998 by and is headquartered in Menlo Park, CA.

Description

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer. In addition, it develops CORT125134 for the treatment of patients with Cushing's syndrome and solid-tumor cancers; and CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortisol activity at glucocorticoid receptor. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading